SARS-CoV-2 infection of non-neuronal cells, not neurons, may drive loss of smell in patients with COVID-19

A new study of human olfactory cells has revealed that viral invasion of supportive cells in the nasal cavity might be driving the loss of smell seen in some patients with COVID-19. The findings show that non-neuronal cells in the brain and nose express genes critical for SARS-CoV-2 entry, while neurons do not; therefore, non-neuronal…

Details

How COVID-19 causes smell loss

At a glance: Loss of smell is the main neurological symptom of COVID-19, but the underlying mechanism has been unclear New study shows infection of nonneuronal supporting cells in the nose and forebrain may be responsible for loss of smell in patients with COVID-19 Findings suggest olfactory sensory neurons are not vulnerable to SARS-CoV-2…

Details

Elevated levels of a specific protein found to correlate with inflammatory symptom severity in COVID

A new study found raised levels of transforming growth factor beta-induced protein (TGFBIp) in blood sampled from roughly 100 people hospitalized for COVID-19, and further found that elevated levels of both the normal and acetylated forms of TGFBIp correlated with the severity of disease symptoms in these patients. While more work will be required to…

Details

Understanding cardiac anomalies at perinatal phase

In Perinatal Cardiology, fetal cardiology experts provide key information on tools for fetal evaluation through echocardiography / cardiac ultrasonography, with a primary focus on the nature and prenatal detection of structural and functional cardiac heart defects (CHDs). This two-part book will enlighten the readers with details about different types of fetal cardiac abnormalities along with…

Details

Genetic mutations predispose individuals to severe COVID-19

Current observations suggest that the coronavirus SARS-CoV-2 causes severe symptoms mainly in elderly patients with chronic disease. However when two pairs of previously healthy young brothers from two families required mechanical ventilation at the intensive care unit in rapid succession, doctors and researchers at Radboud University Medical Center were inclined to consider that genetic factors…

Details

Dana-Farber to offer first CAR T-cell therapy for mantle cell lymphoma after FDA approval

Today’s Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for mantle cell lymphoma (MCL) represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber Cancer Institute investigators who helped conduct the decisive clinical trial of the therapy. Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) will be…

Details